PMID- 27210871
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20220310
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 37
IP  - 5
DP  - 2016 May 14
TI  - [The roles of serum free light chain ratio in the diagnosis and prognosis of 
      newly diagnosed multiple myeloma].
PG  - 377-82
LID - 10.3760/cma.j.issn.0253-2727.2016.05.005 [doi]
AB  - OBJECTIVE: The roles of serum free light chain ratio (sFLCR) in the diagnosis and 
      prognosis of newly diagnosed multiple myeloma (NDMM) patients were analyzed. 
      METHODS: The clinical data was retrospectively analyzed for 82 newly diagnosed 
      multiple myeloma (NDMM) patients in the first affiliated hospital of Soochow 
      University from September 28, 2012 to July 18, 2105. The serum free light chain 
      levels were measured and kappa/lambda ratios were calculated, so we could analyze the 
      roles of sFLCR in the diagnosis and prognosis of newly diagnosed multiple myeloma 
      (NDMM) patients. RESULTS: It was 85.5% (70/82) positive of M protein by serum 
      protein electrophoresis (SFE) and 93.9%(77/82) by serum immunofixation 
      electrophoresis (IFE). Both sFLC and sFLCR abnormalities were 96.3% (79/82). The 
      estimated 40-months overall survival was 87% for the high free light chain ratio 
      group (sFLCR >/=100 or</=0.01) and 61% for the low free light chain ratio group 
      (0.01<sFLCR<100), respectively, with a statistical significance (P=0.034). 
      Compared with low sFLCR group, high sFLCR group had elevated levels of serum 
      creatinine, bone marrow plasma cells and beta2-MG; lower level of hemoglobin; higher 
      proportion of patients with renal dysfunction and selecting hemodialysis; more 
      patients with DS stage ⅢB and ISS stage Ⅲ; higher proportion of abnormal 
      fluorescence in situ hybridization (FISH) and lambda chain isotype. The low risk group 
      had a rise of kappa chain isotype (all P<0.05). And the difference was not 
      statistically significant when compared with the age, sex, TP, ALB, CRP, LDH, 
      Ca(2+), M protein and chromosome. After 3-4 courses of induction chemotherapy, 
      based on the response criteria formulated by the IMWG for patients who could 
      reach the Very Good Remission or better (VGPR+), the responses of VGPR+ were 
      45.2% (19/42) in high sFLCR group and 72.5% (29/40) in low group (P=0.012). Among 
      them, there were 14 cases (17.1%) of NDMM with renal dysfunction. The 2-year 
      survivals in patients with renal insufficiency and normal renal function were 
      85.7% and 91.2% (P=0.894), respectively. CONCLUSION: sFLC assay is much more 
      sensitive than the common methods used, such as SPE and IFE for the diagnosis of 
      MM. The patients with significantly abnormal sFLCR have more tumor burden, higher 
      aggressive progression, and adverse prognosis. Compared with the patients who 
      have normal renal function, the patients with renal insufficiency acquire the 
      same effect after receiving reasonable treatment actively.
FAU - Wang, P F
AU  - Wang PF
AD  - First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 
      Key Laboratory of thrombosis and hemostasis of Ministry of health , Hematology 
      Collaborative Innovation Center , Suzhou 215006, China.
FAU - Xu, Y
AU  - Xu Y
FAU - Yan, S
AU  - Yan S
FAU - Yao, Y
AU  - Yao Y
FAU - Zheng, H F
AU  - Zheng HF
FAU - Ma, L
AU  - Ma L
FAU - Jin, S
AU  - Jin S
FAU - Xu, Y
AU  - Xu Y
FAU - Gong, F R
AU  - Gong FR
FAU - Zhou, J Z
AU  - Zhou JZ
FAU - Chang, H R
AU  - Chang HR
FAU - Fu, C C
AU  - Fu CC
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Myeloma Proteins)
RN  - 0 (multiple myeloma M-proteins)
SB  - IM
MH  - Bone Marrow Cells
MH  - Humans
MH  - Immunoglobulin Light Chains/*blood
MH  - In Situ Hybridization, Fluorescence
MH  - Multiple Myeloma/blood/*diagnosis
MH  - Myeloma Proteins/chemistry
MH  - Prognosis
MH  - Renal Insufficiency/complications
MH  - Retrospective Studies
PMC - PMC7348314
EDAT- 2016/05/24 06:00
MHDA- 2017/01/31 06:00
PMCR- 2016/05/01
CRDT- 2016/05/24 06:00
PHST- 2016/05/24 06:00 [entrez]
PHST- 2016/05/24 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - cjh-37-05-377 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2016.05.005 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2016 May 14;37(5):377-82. doi: 
      10.3760/cma.j.issn.0253-2727.2016.05.005.